1. Home
  2. WYY vs NSPR Comparison

WYY vs NSPR Comparison

Compare WYY & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo WidePoint Corporation

WYY

WidePoint Corporation

HOLD

Current Price

$5.21

Market Cap

48.1M

Sector

Technology

ML Signal

HOLD

Logo InspireMD Inc.

NSPR

InspireMD Inc.

HOLD

Current Price

$1.35

Market Cap

72.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WYY
NSPR
Founded
1991
2005
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Medical/Dental Instruments
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
48.1M
72.1M
IPO Year
2005
2009

Fundamental Metrics

Financial Performance
Metric
WYY
NSPR
Price
$5.21
$1.35
Analyst Decision
Strong Buy
Buy
Analyst Count
3
1
Target Price
$8.67
$4.00
AVG Volume (30 Days)
32.6K
44.8K
Earning Date
05-14-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$150,545,364.00
$2,310,000.00
Revenue This Year
$14.41
$57.98
Revenue Next Year
$11.41
$95.41
P/E Ratio
N/A
N/A
Revenue Growth
5.59
N/A
52 Week Low
$2.71
$1.28
52 Week High
$7.55
$2.93

Technical Indicators

Market Signals
Indicator
WYY
NSPR
Relative Strength Index (RSI) 53.40 32.05
Support Level $4.95 N/A
Resistance Level $5.85 $2.50
Average True Range (ATR) 0.29 0.11
MACD 0.03 -0.02
Stochastic Oscillator 80.41 14.69

Price Performance

Historical Comparison
WYY
NSPR

About WYY WidePoint Corporation

WidePoint Corp is a provider of Technology Management as a Service (TMaaS) that consists of federally certified communications management, identity management, interactive bill presentment and analytics, and an Information Technology as a Service solution. Its solutions include Telecom Lifecycle Management, Digital billing communications solutions, and Mobile and Identity management. Geographically, the company generates a majority of its revenue from the United States and the rest from Europe.

About NSPR InspireMD Inc.

InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.

Share on Social Networks: